Irritable Bowel Syndrome Clinical Trial
Official title:
A Randomized, Double-blind, Cross-over Trial of the Effect of CanChew® Cannabidiol (CBD) Containing Chewing Gum on Patients With Irritable Bowel Syndrome
Rationale: IBS is the most common functional gastrointestinal disorder with a prevalence
worldwide ranging from 9-23%. Complaints include abdominal discomfort or pain and altered
bowel habits. Although the condition is not life-threatening, it strongly impairs quality of
life and up to now there is no cure for IBS. It is assumed that IBS symptoms are related to
a combination of altered gut motility and secretion, and visceral hypersensitivity. However,
its primary cause still remains largely unknown. The endocannabinoid system, together with
some functionally related receptors is among the biological targets considered promising for
treatment. Modulation of the CB1 , CB2 and related receptors or enzymes of the
endocannabinoid system in a broader sense by (endo) cannabinoids or (and) structurally
related lipid mediators can influence motility, secretions and decrease hypersensitivity in
the gut. Among the plant-derived cannabinoids or so called 'phytocannabinoids', cannabidiol
(CBD) is of special interest as it has shown therapeutic potential in preclinical studies
and a growing number of case-reports. CBD is a non-specific phytocannabinoid displaying a
broad but weak receptor interaction profile. In contrast to the well-known THC from Cannabis
sativa, CBD is not psychoactive and often also present in those Cannabis varieties that are
not used for their psychoactive properties but for industrial (fibre) or food properties
(oil, flour and seeds) instead. Based on preclinical studies and in vitro data we
hypothesize that CBD might be able to relieve symptoms of IBS, including pain in patients
with IBS. The chewing gum is to be taken 'on demand' and may have some additional perceived
positive effects.
Objective: To investigate whether the use of a CBD-containing preparation in the form of
CanChew® chewing gum can contribute to a reduction of IBS symptoms and an improvement of
perceived wellbeing in patients with IBS.
Study design: A randomized, double-blind, cross-over trial of 8 weeks in total.
Study population: Adults, aged 18-65, diagnosed according to the ROME III criteria with
Irritable Bowel Syndrome.
Intervention (if applicable): Patients will, in this cross-over study, receive a maximum 6
chewing gums per day, either containing 50 mg of cannabidiol per chewing gum in case of the
CanChew chewing gum, or a placebo chewing gum. This first intervention period will last 3
weeks. Next, participants will undergo a one week wash-out and then switch intervention to
either placebo or the CanChew chewing gum for another 3 weeks.
Main study parameters/endpoints: The main study parameter is a change in pain reduction
perception experienced and measured by the patient using VAS-scales before and after taking
the chewing gum, to be recorded in a diary. Next to this a patient is asked to provide one
VAS score for each completed week. Furthermore, the adequate relief will be measured every
day. At the end of each week patients will also be asked (from their diary) whether they
noticed a change in stool frequency or (and) experienced any side-effects. For the
disease-related quality of life the IBS-QOL will be used. This questionnaire will be filled
out in week 1, 4, 5, and 8.
n/a
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
| Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
| Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
| Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
| Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
| Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
| Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
| Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
| Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
| Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
| Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
| Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
| Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
| Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
| Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
| Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
| Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
| Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |